<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pediatr</journal-id><journal-title>BMC Pediatrics</journal-title><issn pub-type="epub">1471-2431</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16719931</article-id><article-id pub-id-type="pmc">1523329</article-id><article-id pub-id-type="publisher-id">1471-2431-6-17</article-id><article-id pub-id-type="doi">10.1186/1471-2431-6-17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" corresp="yes" contrib-type="author"><name><surname>Lucidi</surname><given-names>V</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lucidi@opbg.net</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Tozzi</surname><given-names>AE</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>alberto.tozzi@opbg.net</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Bella</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bella@opbg.net</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Turchetta</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>turchetta@opbg.net</email></contrib></contrib-group><aff id="I1"><label>1</label>Ospedale Bambino Gesù, Department of Pediatrics, Cystic Fibrosis Unit, Rome, Italy</aff><aff id="I2"><label>2</label>Ospedale Bambino Gesù, Epidemiology Unit, Rome, Italy</aff><aff id="I3"><label>3</label>Ospedale Bambino Gesù, Department of Pediatrics, Respiratory Fisiopathology Unit, Rome, Italy</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>24</day><month>5</month><year>2006</year></pub-date><volume>6</volume><fpage>17</fpage><lpage>17</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2431/6/17"></ext-link><history><date date-type="received"><day>2</day><month>9</month><year>2005</year></date><date date-type="accepted"><day>24</day><month>5</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Lucidi et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Lucidi et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3211" xml_f="3221" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3232" xml_f="4056" txt_i="22" txt_f="846">Chronic neutrophil inflammation of the respiratory tract tissues plays a key role in the pathogenesis and in prognosis of cystic fibrosis (CF). It is evident that an anti-inflammatory therapy represents an important step in the treatment of CF patients. Corticosteroids and ibuprofen have been proven to slow down the impairment of the pulmonary function in CF patients but their use is limited by the frequency of adverse events. A novel strategy for delivering low doses of steroids for long periods through the infusion of autologous erythrocytes loaded with dexamethasone has been recently set up. A recent study suggested the feasibility of therapy with low doses of corticosteroids delivered through engineered erythrocytes in CF patients. This study presents a further analysis of safety and efficacy of this therapy.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="4097" xml_f="4104" txt_i="848" txt_f="855">Methods</offsets></title><p><offsets xml_i="4115" xml_f="4944" txt_i="856" txt_f="1682">The treatment group was not randomised and the assignment was based on the patient's consent. Patients entered the study if they had a forced expiratory volume in 1 second (FEV1) &lt;70%, puberty development completed, pancreatic insufficiency, and chronic pulmonary infection requiring frequent cycles of intravenous antibiotic therapy. Patients were excluded if they underwent systemic corticosteriod therapy in the three months preceding the experimental treatment or were on therapy with non-steroidal anti inflammatory drugs (NASDs), or if they had liver CF disease, allergic bronchopulmonary aspergillosis, or positive tuberculin test. Controls were patients who followed a standard treatment, who fulfilled the enrolment criteria, and who were matched to the experimental group by gender, age, and severity of the disease.</offsets></p></sec><sec><title><offsets xml_i="4966" xml_f="4973" txt_i="1684" txt_f="1691">Results</offsets></title><p><offsets xml_i="4984" xml_f="5688" txt_i="1692" txt_f="2396">Nine patients in the experimental group received the treatment once a month for a period of 24 month. Patients did not develop diabetes, cataract, or hypertension, or other typical side effects of steroid treatment during the follow up period. There was a constant improvement of FEV1 in patients undergoing the experimental treatment compared to a gradual decrease of the same parameter in the standard therapy group (P = 0.04). The average of clinic and radiological indexes did not vary. The number of infective relapses that have required antibiotic intravenous therapy was not different in the two groups, although the average of these episodes was slightly higher in the experimental therapy group.</offsets></p></sec><sec><title><offsets xml_i="5710" xml_f="5720" txt_i="2398" txt_f="2408">Conclusion</offsets></title><p><offsets xml_i="5731" xml_f="6122" txt_i="2409" txt_f="2800">Intraerythrocyte corticosteroid treatment may stabilize the respiratory function in CF patients but is often considered too invasive by patients. The results obtained by our study may help planning an experimental, controlled, randomised study. A sample size of 150 patients per group would be sufficient for demonstrating such a difference with a 95% confidence interval and a power of 90%.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="6184" xml_f="6194" txt_i="2809" txt_f="2819">Background</offsets></title><p><offsets xml_i="6205" xml_f="6462" txt_i="2820" txt_f="3077">Chronic neutrophil inflammation of the respiratory tract tissues plays a key role in the pathogenesis of cystic fybrosis (CF). It has been shown that CF breast-fed children have a bronchopulmonary inflammation before the appearance of bacterial infections [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6493" xml_f="6494" txt_i="3077" txt_f="3078">1</offsets></xref><offsets xml_i="6501" xml_f="6502" txt_i="3078" txt_f="3079">-</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6533" xml_f="6534" txt_i="3079" txt_f="3080">3</offsets></xref><offsets xml_i="6541" xml_f="6664" txt_i="3080" txt_f="3203">]. It is therefore evident that an anti-inflammatory therapy represents an important step in the treatment of CF patients [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6695" xml_f="6696" txt_i="3203" txt_f="3204">4</offsets></xref><offsets xml_i="6703" xml_f="6705" txt_i="3204" txt_f="3206">].</offsets></p><p><offsets xml_i="6712" xml_f="6852" txt_i="3207" txt_f="3347">Some authors already expressed the hope that uncertainties on the use of anti-inflammatory therapy in CF patients should have been removed [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6883" xml_f="6884" txt_i="3347" txt_f="3348">5</offsets></xref><offsets xml_i="6891" xml_f="7003" txt_i="3348" txt_f="3460">], and new evidences supporting the role of inflammation in the pathogenesis of CF have recently been gathered [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7034" xml_f="7035" txt_i="3460" txt_f="3461">6</offsets></xref><offsets xml_i="7042" xml_f="7043" txt_i="3461" txt_f="3462">-</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7074" xml_f="7075" txt_i="3462" txt_f="3463">8</offsets></xref><offsets xml_i="7082" xml_f="7084" txt_i="3463" txt_f="3465">].</offsets></p><p><offsets xml_i="7091" xml_f="7282" txt_i="3466" txt_f="3657">Corticosteroids and ibuprofen have been proven to slow down the impairment of the pulmonary function in CF patients but their use is limited by the frequency and severity of adverse effects [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="7313" xml_f="7314" txt_i="3657" txt_f="3658">9</offsets></xref><offsets xml_i="7321" xml_f="7322" txt_i="3658" txt_f="3659">-</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="7354" xml_f="7356" txt_i="3659" txt_f="3661">12</offsets></xref><offsets xml_i="7363" xml_f="7365" txt_i="3661" txt_f="3663">].</offsets></p><p><offsets xml_i="7372" xml_f="7581" txt_i="3664" txt_f="3873">Indeed, CF patients are often treated with corticosteroids during pulmonary infective breakthroughs, as shown by Oermann who reported that 41% of physicians in CF centres prescribe long-lasting oral steroids [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="7613" xml_f="7615" txt_i="3873" txt_f="3875">13</offsets></xref><offsets xml_i="7622" xml_f="8153" txt_i="3875" txt_f="4406">]. Pharmacological activity of corticosteroids varies from one patient to another depending on drug absorption especially if administered by aerosol. New systems for slow release of corticosteroids which maintain therapeutic systemic concentrations for a prolonged time using a low quantity of drug, would therefore be useful for the treatment of CF patients. A novel strategy for delivering low doses of steroids for long periods through the infusion of autologous erythrocytes loaded with dexamethasone has been recently set up [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="8185" xml_f="8187" txt_i="4406" txt_f="4408">14</offsets></xref><offsets xml_i="8194" xml_f="8195" txt_i="4408" txt_f="4409">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="8227" xml_f="8229" txt_i="4409" txt_f="4411">15</offsets></xref><offsets xml_i="8236" xml_f="8394" txt_i="4411" txt_f="4569">]. It has been demonstrated that encapsulated erythrocites present normal morphology, normal metabolic and antigenic properties, and normal survival in vivo [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="8426" xml_f="8428" txt_i="4569" txt_f="4571">16</offsets></xref><offsets xml_i="8435" xml_f="8654" txt_i="4571" txt_f="4790">]. Furthermore a pharmacokinetics study demonstrated that consistent and persistent plasma level can be maintained up to one month after infusion independently of the starting amount of encapsulated dexamethasone 21-P [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="8686" xml_f="8688" txt_i="4790" txt_f="4792">17</offsets></xref><offsets xml_i="8695" xml_f="8697" txt_i="4792" txt_f="4794">].</offsets></p><p><offsets xml_i="8704" xml_f="8899" txt_i="4795" txt_f="4990">A recent study suggested the feasibility and a favourable effect of therapy with low doses of corticosteroids delivered through engineered erythrocytes in CF patients up to 15 months of therapy [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="8931" xml_f="8933" txt_i="4990" txt_f="4992">17</offsets></xref><offsets xml_i="8940" xml_f="9078" txt_i="4992" txt_f="5130">]. This study extends the follow up of these patients to 24 months and presents a further analysis of safety and efficacy of this therapy.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="9119" xml_f="9126" txt_i="5132" txt_f="5139">Methods</offsets></title><sec><title><offsets xml_i="9146" xml_f="9162" txt_i="5140" txt_f="5156">Study population</offsets></title><p><offsets xml_i="9173" xml_f="9349" txt_i="5157" txt_f="5333">Patients were enrolled at the CF Unit of the Bambino Gesù Hospital, Rome, if they had a definite diagnosis of CF through at least two sweat tests according to Gibson and Cook [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="9381" xml_f="9383" txt_i="5333" txt_f="5335">18</offsets></xref><offsets xml_i="9390" xml_f="10095" txt_i="5335" txt_f="6031">], and through a research of mutation of CFTR gene. Patients entered the study if they had a forced expiratory volume in 1 second (FEV1) &lt;70%, puberty development completed (Tanner V level stage), pancreatic insufficiency (fat balance evaluation &lt;93% and/or faecal elastase &lt;200 μg/g faeces), and chronic bacterial pulmonary infection requiring frequent cycles of intravenous antibiotic therapy. Patients were excluded if they underwent systemic corticosteroid therapy in the three months preceding the experimental treatment or were on therapy with non-steroidal anti-inflammatory drugs (NSADs), if they had liver CF disease, allergic bronchopulmonary aspergillosis, or positive tuberculin test.</offsets></p><p><offsets xml_i="10102" xml_f="10657" txt_i="6032" txt_f="6587">The study has been approved by the Ethics Committee of Paediatric Hospital Bambino Gesù and all the patients (or their parents/guardians) have signed an informed consent. Two study groups were considered for this study: individuals who underwent the experimental treatment were compared to a group of patients who followed a standard treatment, who fulfilled the enrolment criteria, and who were matched to the experimental group by gender, age ( ± 2 years), and severity of the disease (FEV1 at enrolment ± 10%; Shwachman index ± 20; Crispin score ± 5) [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="10689" xml_f="10691" txt_i="6587" txt_f="6589">19</offsets></xref><offsets xml_i="10698" xml_f="10699" txt_i="6589" txt_f="6590">,</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="10731" xml_f="10733" txt_i="6590" txt_f="6592">20</offsets></xref><offsets xml_i="10740" xml_f="10742" txt_i="6592" txt_f="6594">].</offsets></p><p><offsets xml_i="10749" xml_f="10837" txt_i="6595" txt_f="6683">The treatment was not randomised and the assignment was based on the patient's consent. </offsets></p></sec><sec><title><offsets xml_i="10859" xml_f="10868" txt_i="6685" txt_f="6694">Treatment</offsets></title><p><offsets xml_i="10879" xml_f="11168" txt_i="6695" txt_f="6984">The experimental treatment consists in collecting 50 ml of blood into a syringe containing heparin. Erythrocytes are loaded with dexamethasone 21-phosphate through lysis in a hypotonic solution, the drug is entrapped, and the cells are resealed with the use of a "Red Cell Loader" device [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="11200" xml_f="11202" txt_i="6984" txt_f="6986">14</offsets></xref><offsets xml_i="11209" xml_f="11400" txt_i="6986" txt_f="7177">]. Loaded red cells are then reinfused into the original patient resulting in released quantities of dexamethasone 21-phosphate ranging from 0.1 to 0.2 nmol/ml of plasma for up to one month [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="11432" xml_f="11434" txt_i="7177" txt_f="7179">17</offsets></xref><offsets xml_i="11441" xml_f="11598" txt_i="7179" txt_f="7336">]. The entire procedure requires two hours to be completed. Patients in the experimental group received the treatment once a month for a period of 24 months.</offsets></p><p><offsets xml_i="11605" xml_f="11893" txt_i="7337" txt_f="7625">All patients followed standard prevention therapies, treatment of chronic pulmonary infection and pancreatic insufficiency (aerosol therapy with DNase and beclomethasone, Pulmozyme, daily FKT, vitamins, pancreatic enzymes), and received antibiotic treatment in case of infective relapses.</offsets></p></sec><sec><title><offsets xml_i="11915" xml_f="11936" txt_i="7627" txt_f="7648">Follow up and outcome</offsets></title><p><offsets xml_i="11947" xml_f="13199" txt_i="7649" txt_f="8901">All patients underwent Bone Mineralometry (BM), ocular tonometry, and arterial pressure measurement before entering the trial. Clinical, bacterial, and functional respiratory data were monitored for 12 months before and in the 24 months after starting the experimental treatment, and for a corresponding period of time (36 months) in patients assigned to standard treatment. Patients were continuously monitored for the inflammatory (c-reactive protein, erythrosedimentation rate), infective (white blood cell count, culture of expectoration with antibiogram), and nutritional parameters (weight), and underwent functional pulmonary tests (FEV1 and forced vital capacity (FVC) at any control. All patients were invited to be visited once a month. As for safety of treatment, we studied the oral glucose tolerance test (every year), glycated haemoglobin (every month), bone mineral density, and ocular tonometry (at the end of the study), while blood pressure, skin lesions, and other side effects were monitored at each visit. We have analysed Shwachman and Crispin indexes at the end of treatment, and FEV1 trend over time. Episodes of infective bronchopulmonary breakthrough according to Ramsey criteria were also considered in the outcome measures [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="13231" xml_f="13233" txt_i="8901" txt_f="8903">21</offsets></xref><offsets xml_i="13240" xml_f="13308" txt_i="8903" txt_f="8971">] as well as the number of visits performed during the study period.</offsets></p></sec><sec><title><offsets xml_i="13330" xml_f="13350" txt_i="8973" txt_f="8993">Statistical analysis</offsets></title><p><offsets xml_i="13361" xml_f="13556" txt_i="8994" txt_f="9189">Since this study was designed as a pilot trial we did not perform any estimation of the sample size required for showing any effect of the treatment or any difference in the rate of side effects.</offsets></p><p><offsets xml_i="13563" xml_f="13963" txt_i="9190" txt_f="9590">Variations in the Shwachman and Crispin indexes were evaluated through the Student t test. We have used the standard deviations (Z scores) of FEV1 for each visit based on the patient average of measures during the 12 months preceding the trial. The mean and standard deviation of FEV1 Z scores were calculated for each time interval. A general linear model repeated-measures ANOVA was used to compare</offsets></p><p><offsets xml_i="13970" xml_f="14419" txt_i="9591" txt_f="10040">FEV1 Z scores in patients with the experimental treatment with those with standard therapy. Linear regression was used to describe the FEV1 Z score trend over time. The incidence density rates of infectious episodes have been compared through the Student t test, whereas frequencies of side effects in the two groups have been compared through the Chi square test. Analyses were performed with the statistical package SPSS (version 11.5, SPSS, Inc).</offsets></p></sec></sec><sec><title><offsets xml_i="14447" xml_f="14454" txt_i="10043" txt_f="10050">Results</offsets></title><p><offsets xml_i="14465" xml_f="15142" txt_i="10051" txt_f="10728">We enrolled 17 patients in the experimental group and nine patients in the standard treatment group. Of the 17 patients in the experimental group, eight received less than four administrations of dexamethasone phosphate through loaded erythrocytes and therefore were excluded from further analyses. These patients (2 males, 6 females; median age 23,5; SD:7 years) had similar demographic characteristics of patients continuing the experimental therapy and did not continue the red cell loading because of personal discomfort in receiving the treatment, or for difficulties in being regularly visited and treated by our centre. None of these patients developed any side effects.</offsets></p><p><offsets xml_i="15149" xml_f="15215" txt_i="10729" txt_f="10795">The baseline characteristics of patients are illustrated in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="15247" xml_f="15248" txt_i="10795" txt_f="10796">1</offsets></xref><offsets xml_i="15255" xml_f="15358" txt_i="10796" txt_f="10899">. The two groups showed similar demographic and clinical characteristics at the beginning of the trial.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="15406" xml_f="15413" txt_i="10900" txt_f="10907">Table 1</offsets></label><caption><p><offsets xml_i="15433" xml_f="15495" txt_i="10907" txt_f="10969">Baseline characteristics of the patients enrolled in the trial</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold><offsets xml_i="15589" xml_f="15625" txt_i="10971" txt_f="11007">Erythrocyte mediated steroid therapy</offsets></bold></td><td align="left"><bold><offsets xml_i="15660" xml_f="15676" txt_i="11008" txt_f="11024">Ordinary therapy</offsets></bold></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="15729" xml_f="15744" txt_i="11025" txt_f="11040">No. of patients</offsets></td><td align="left"><offsets xml_i="15766" xml_f="15767" txt_i="11041" txt_f="11042">9</offsets></td><td align="left"><offsets xml_i="15789" xml_f="15790" txt_i="11043" txt_f="11044">9</offsets></td></tr><tr><td align="left"><offsets xml_i="15821" xml_f="15833" txt_i="11045" txt_f="11057">Females, no.</offsets></td><td align="left"><offsets xml_i="15855" xml_f="15856" txt_i="11058" txt_f="11059">5</offsets></td><td align="left"><offsets xml_i="15878" xml_f="15879" txt_i="11060" txt_f="11061">5</offsets></td></tr><tr><td align="left"><offsets xml_i="15910" xml_f="15941" txt_i="11062" txt_f="11093">Age at enrolment, years (range)</offsets></td><td align="left"><offsets xml_i="15963" xml_f="15975" txt_i="11094" txt_f="11106">19.8 (15–26)</offsets></td><td align="left"><offsets xml_i="15997" xml_f="16009" txt_i="11107" txt_f="11119">20.0 (13–26)</offsets></td></tr><tr><td align="left"><offsets xml_i="16040" xml_f="16069" txt_i="11120" txt_f="11149">Colonization by P. aeruginosa</offsets></td><td align="left"><offsets xml_i="16091" xml_f="16092" txt_i="11150" txt_f="11151">6</offsets></td><td align="left"><offsets xml_i="16114" xml_f="16115" txt_i="11152" txt_f="11153">7</offsets></td></tr><tr><td align="left"><offsets xml_i="16146" xml_f="16162" txt_i="11154" txt_f="11170">Colonization by </offsets><italic><offsets xml_i="16170" xml_f="16180" txt_i="11170" txt_f="11180">B. cepacia</offsets></italic></td><td align="left"><offsets xml_i="16211" xml_f="16212" txt_i="11181" txt_f="11182">3</offsets></td><td align="left"><offsets xml_i="16234" xml_f="16235" txt_i="11183" txt_f="11184">1</offsets></td></tr><tr><td align="left"><offsets xml_i="16266" xml_f="16282" txt_i="11185" txt_f="11201">Colonization by </offsets><italic><offsets xml_i="16290" xml_f="16311" txt_i="11201" txt_f="11222">Staphilococcus aureus</offsets></italic></td><td align="left"><offsets xml_i="16342" xml_f="16343" txt_i="11223" txt_f="11224">-</offsets></td><td align="left"><offsets xml_i="16365" xml_f="16366" txt_i="11225" txt_f="11226">1</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="16408" xml_f="16689" txt_i="11227" txt_f="11508">Two patients in the experimental treatment group, and two in the standard treatment group had a diagnosis of diabetes type 1 before entering the study. Six patients in the experimental treatment group and nine in the standard treatment group received TOBI therapy during the study.</offsets></p><p><offsets xml_i="16696" xml_f="17067" txt_i="11509" txt_f="11880">None of the patients in the experimental treatment group developed diabetes, while two patients in the standard treatment group did (22%). We did not observe any decrease of bone mineral density, or any increase of ocular pressure in the two groups of patients. No patients developed cataract, arterial hypertension, or cutaneous striae rubrae, and no death was observed.</offsets></p><p><offsets xml_i="17074" xml_f="17174" txt_i="11881" txt_f="11981">Shwachman and Crispin scores did not vary in the two groups during follow up, as indicated in Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="17206" xml_f="17207" txt_i="11981" txt_f="11982">2</offsets></xref><offsets xml_i="17214" xml_f="17286" txt_i="11982" txt_f="12054">. Average FEV1 at enrolment, at 12, and 24 months are reported in Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="17318" xml_f="17319" txt_i="12054" txt_f="12055">3</offsets></xref><offsets xml_i="17326" xml_f="17618" txt_i="12055" txt_f="12347">. Despite we did not observe any significant difference in the average FEV1 due to the small sample size, these measures indicate an opposite trend in the two groups: FEV1 tended to increase in the experimental treatment group, while in the standard treatment a decreasing trend was observed.</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="17666" xml_f="17673" txt_i="12348" txt_f="12355">Table 2</offsets></label><caption><p><offsets xml_i="17693" xml_f="17752" txt_i="12355" txt_f="12414">Variation of Shwachman and Crispin indexes during follow up</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold><offsets xml_i="17846" xml_f="17882" txt_i="12416" txt_f="12452">Erythrocyte mediated steroid therapy</offsets></bold></td><td align="left"><bold><offsets xml_i="17917" xml_f="17933" txt_i="12453" txt_f="12469">Ordinary therapy</offsets></bold></td><td align="left"><bold><offsets xml_i="17968" xml_f="17975" txt_i="12470" txt_f="12477">P value</offsets></bold></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="18028" xml_f="18070" txt_i="12478" txt_f="12520">Mean Shwachman index at enrolment (95% CI)</offsets></td><td align="left"><offsets xml_i="18092" xml_f="18109" txt_i="12521" txt_f="12538">71.3 (36.2–106.4)</offsets></td><td align="left"><offsets xml_i="18131" xml_f="18148" txt_i="12539" txt_f="12556">70.9 (41.3–100.5)</offsets></td><td align="left"><offsets xml_i="18170" xml_f="18174" txt_i="12557" txt_f="12561">0.73</offsets></td></tr><tr><td align="left"><offsets xml_i="18205" xml_f="18260" txt_i="12562" txt_f="12617">Mean Shwachman index at 12 months of follow up (95% CI)</offsets></td><td align="left"><offsets xml_i="18282" xml_f="18299" txt_i="12618" txt_f="12635">62.6 (20.0–103.2)</offsets></td><td align="left"><offsets xml_i="18321" xml_f="18337" txt_i="12636" txt_f="12652">68.4 (39.2–97.6)</offsets></td><td align="left"><offsets xml_i="18359" xml_f="18363" txt_i="12653" txt_f="12657">0.68</offsets></td></tr><tr><td align="left"><offsets xml_i="18394" xml_f="18449" txt_i="12658" txt_f="12713">Mean Shwachman index at 24 months of follow up (95% CI)</offsets></td><td align="left"><offsets xml_i="18471" xml_f="18488" txt_i="12714" txt_f="12731">66.8 (21.9–111.7)</offsets></td><td align="left"><offsets xml_i="18510" xml_f="18526" txt_i="12732" txt_f="12748">68.0 (37.6–98.4)</offsets></td><td align="left"><offsets xml_i="18548" xml_f="18552" txt_i="12749" txt_f="12753">0.83</offsets></td></tr><tr><td align="left"><offsets xml_i="18583" xml_f="18624" txt_i="12754" txt_f="12795">Mean Crispin index at enrollment (95% CI)</offsets></td><td align="left"><offsets xml_i="18646" xml_f="18661" txt_i="12796" txt_f="12811">13.7 (4.5–22.6)</offsets></td><td align="left"><offsets xml_i="18683" xml_f="18698" txt_i="12812" txt_f="12827">12.7 (5.3–20.1)</offsets></td><td align="left"><offsets xml_i="18720" xml_f="18724" txt_i="12828" txt_f="12832">0.76</offsets></td></tr><tr><td align="left"><offsets xml_i="18755" xml_f="18808" txt_i="12833" txt_f="12886">Mean Crispin index at 24 months of follow up (95% CI)</offsets></td><td align="left"><offsets xml_i="18830" xml_f="18845" txt_i="12887" txt_f="12902">13.6 (5.2–22.0)</offsets></td><td align="left"><offsets xml_i="18867" xml_f="18882" txt_i="12903" txt_f="12918">12.9 (5.9–19.9)</offsets></td><td align="left"><offsets xml_i="18904" xml_f="18908" txt_i="12919" txt_f="12923">0.48</offsets></td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label><offsets xml_i="18991" xml_f="18998" txt_i="12924" txt_f="12931">Table 3</offsets></label><caption><p><offsets xml_i="19018" xml_f="19052" txt_i="12931" txt_f="12965">Variation of FEV1 during follow up</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold><offsets xml_i="19146" xml_f="19182" txt_i="12967" txt_f="13003">Erythrocyte mediated steroid therapy</offsets></bold></td><td align="left"><bold><offsets xml_i="19217" xml_f="19233" txt_i="13004" txt_f="13020">Ordinary therapy</offsets></bold></td><td align="left"><bold><offsets xml_i="19268" xml_f="19275" txt_i="13021" txt_f="13028">P value</offsets></bold></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="19328" xml_f="19376" txt_i="13029" txt_f="13077">FEV1 at enrolment (-12 months), average (95% CI)</offsets></td><td align="left"><offsets xml_i="19398" xml_f="19414" txt_i="13078" txt_f="13094">53.8 (25.6–82.0)</offsets></td><td align="left"><offsets xml_i="19436" xml_f="19452" txt_i="13095" txt_f="13111">56.8 (30.0–83.6)</offsets></td><td align="left"><offsets xml_i="19474" xml_f="19478" txt_i="13112" txt_f="13116">0.68</offsets></td></tr><tr><td align="left"><offsets xml_i="19509" xml_f="19543" txt_i="13117" txt_f="13151">FEV1 at time +12, average (95% CI)</offsets></td><td align="left"><offsets xml_i="19565" xml_f="19581" txt_i="13152" txt_f="13168">56.7 (23.8–89.6)</offsets></td><td align="left"><offsets xml_i="19603" xml_f="19619" txt_i="13169" txt_f="13185">55.1 (26.5–83.7)</offsets></td><td align="left"><offsets xml_i="19641" xml_f="19645" txt_i="13186" txt_f="13190">0.83</offsets></td></tr><tr><td align="left"><offsets xml_i="19676" xml_f="19710" txt_i="13191" txt_f="13225">FEV1 at time +24, average (95% CI)</offsets></td><td align="left"><offsets xml_i="19732" xml_f="19748" txt_i="13226" txt_f="13242">59.8 (22.4–97.2)</offsets></td><td align="left"><offsets xml_i="19770" xml_f="19786" txt_i="13243" txt_f="13259">53.2 (21.7–84.7)</offsets></td><td align="left"><offsets xml_i="19808" xml_f="19812" txt_i="13260" txt_f="13264">0.48</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="19854" xml_f="19902" txt_i="13265" txt_f="13313">The analysis of FEV1 Z scores over time (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="19932" xml_f="19933" txt_i="13313" txt_f="13314">1</offsets></xref><offsets xml_i="19940" xml_f="20535" txt_i="13314" txt_f="13909">) confirmed opposite trends in the two groups. In the experimental treatment group we observed a progressive improvement of FEV1 compared to the average FEV1 observed before starting experimental therapy. At the end of the follow up period, FEV1 in the experimental treatment group was nearly one standard deviation higher than the reference period. On the contrary, in patients with standard treatment we observed a progressive decrease of FEV1 with a value at 24 months 1.5 standard deviations less than the reference period. The differences observed were statistically significant (P = 0.04).</offsets></p><fig position="float" id="F1"><label><offsets xml_i="20576" xml_f="20584" txt_i="13910" txt_f="13918">Figure 1</offsets></label><caption><p><offsets xml_i="20604" xml_f="20927" txt_i="13918" txt_f="14241">Comparison of FEV1 z-scores in treated and untreatedpatients over time. Continuous lines represent the average z-score ofFEV1 by month. Dotted lines represent the interpolation of the z-scores by linear regression. Comparison of the two groups through general linear model repeated-measures. ANOVA yielded a P value = 0.04.</offsets></p></caption><graphic xlink:href="1471-2431-6-17-1"></graphic></fig><p><offsets xml_i="20999" xml_f="21445" txt_i="14242" txt_f="14685">Patients in the experimental treatment group underwent a number of visits higher than the standard treatment group during follow up (experimental treatment: 1.1 visit per person month; standard treatment: 0.7 visit per person month; P &lt; 0.01). The incidence of infectious episodes was slightly higher in patients who underwent the experimental treatment (experimental treatment: 0.24 per person month; standard: 0.18 per person month; P=0.08).</offsets></p><p><offsets xml_i="21452" xml_f="21728" txt_i="14686" txt_f="14962">None of the eight patients originally enrolled in the experimental therapy group who did not complete the study died or underwent transplantation, but all of them had a FEV1 stable or lower than measured at the beginning of the trial compared to that measured after 24 months.</offsets></p></sec><sec><title><offsets xml_i="21750" xml_f="21760" txt_i="14964" txt_f="14974">Discussion</offsets></title><p><offsets xml_i="21771" xml_f="21955" txt_i="14975" txt_f="15159">This study provides further elements supporting that therapy with dexamethasone 21-phosphate-delivered in autologous erythrocytes may be safe and moderately efficacious in CF patients.</offsets></p><p><offsets xml_i="21962" xml_f="22141" txt_i="15160" txt_f="15339">An earlier study performed on the same patients focused on pharmacokinetics and technical details of therapy with dexamethasone 21-phosphate-delivered in autologous erythrocytes [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="22173" xml_f="22175" txt_i="15339" txt_f="15341">17</offsets></xref><offsets xml_i="22182" xml_f="22531" txt_i="15341" txt_f="15690">]. In the present manuscript we reviewed FEV1 values over time in the same patients, and prolonged the follow up period. The present results substantially reduce the apparent effect of treatment on functional respiratory tests previously reported. However, the benefits associated with this therapy seem to be extended beyond 15 months of follow up.</offsets></p><p><offsets xml_i="22538" xml_f="22705" txt_i="15691" txt_f="15858">The availability of a safe means to administer corticosteroids may be advantageous for CF patients, as well as for other diseases requiring chronic use of these drugs.</offsets></p><p><offsets xml_i="22712" xml_f="22972" txt_i="15859" txt_f="16119">Studies performed in North America on CF patients indicated that treatment with oral steroids was efficacious in improving respiratory function but it caused several adverse effects, such as a significant modification of glucose metabolism and growth failure [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="23004" xml_f="23006" txt_i="16119" txt_f="16121">10</offsets></xref><offsets xml_i="23013" xml_f="23014" txt_i="16121" txt_f="16122">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="23046" xml_f="23048" txt_i="16122" txt_f="16124">11</offsets></xref><offsets xml_i="23055" xml_f="23555" txt_i="16124" txt_f="16624">], particularly after two years of treatment. In fact, the low doses of steroids administered with loaded erythrocytes may reduce these side effects. All patients included in this study completed sexual development and therefore we were not able to measure any effect on growth. However, during the follow up period no patients in the experimental group developed diabetes, cataract, or hypertension or other typical side effects of steroid treatment such as Cushingoid aspect or skin manifestations.</offsets></p><p><offsets xml_i="23562" xml_f="23950" txt_i="16625" txt_f="17013">The main result of this study is a constant improvement of FEV1 in patients undergoing the experimental treatment compared to a gradual decrease of the same parameter in the standard therapy group. The average clinic and radiologic indexes did not vary in the two groups since such parameters are certainly less sensitive in defining the patient's pulmonary performance in the short term.</offsets></p><p><offsets xml_i="23957" xml_f="24989" txt_i="17014" txt_f="18046">Although the study was not randomized, the patients of the two group at the beginning of the trial were similar for age, gender, colonization, respiratory function, and disease stage. We did not perform an intention to treat analysis given the exploratory nature of this pilot study. Inclusion of patients originally assigned to the experimental treatment would have resulted, however, in a much smaller difference in FEV1 over time between the two groups. The number of infective relapses that have required antibiotic intravenous therapy, differently from the previous study, was similar in the two groups, although the average number of episodes was slightly higher in the experimental therapy group. The absence of blinding may be theoretically associated with a more strict control of patients in the experimental group and with an early recognition of infective relapses and, therefore, with a timely treatment. The number of visits per month in the experimental group was actually higher than in the standard treatment group.</offsets></p><p><offsets xml_i="24996" xml_f="25184" txt_i="18047" txt_f="18235">Though the experimental therapy included in the study may be useful for controlling chronic inflammation of the airway in CF patients, additional preventive strategies should be developed.</offsets></p></sec><sec><title><offsets xml_i="25206" xml_f="25216" txt_i="18237" txt_f="18247">Conclusion</offsets></title><p><offsets xml_i="25227" xml_f="25709" txt_i="18248" txt_f="18730">Although the number of enrolled patients in our study was too low to draw definite conclusions, this new administration technique seems safe and moderately efficacious despite the very low steroid circulating dose. The results obtained by our study cannot be considered definitive but may help planning an experimental, controlled, randomised study which may give more robust results, and may involve patients of different age groups with different doses and administration schemes.</offsets></p><p><offsets xml_i="25716" xml_f="26476" txt_i="18731" txt_f="19491">Based on means and standard deviations of FEV1 observed at 24 months in this study, a sample size of 150 patients per group would be sufficient for demonstrating such a difference with a 95% confidence interval and a power of 90%. If a clinical trial with a sufficient number of participants will confirm these preliminary results, an important therapeutic tool will be available to improve the prognosis of CF patients. Moreover studies on corticosteroid drugs in CF paediatric patients need at least five years to assess the control of inflammation in the long term and the occurrence of late side effects. Alternative strategies for inflammation control should focus on the immune imbalance which has been found even in young clinically stable CF patients [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="26508" xml_f="26510" txt_i="19491" txt_f="19493">22</offsets></xref><offsets xml_i="26517" xml_f="26519" txt_i="19493" txt_f="19495">].</offsets></p></sec><sec><title><offsets xml_i="26541" xml_f="26560" txt_i="19497" txt_f="19516">Competing interests</offsets></title><p><offsets xml_i="26571" xml_f="26631" txt_i="19517" txt_f="19577">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="26653" xml_f="26675" txt_i="19579" txt_f="19601">Authors' contributions</offsets></title><p><offsets xml_i="26686" xml_f="26888" txt_i="19602" txt_f="19804">VL, SB, and AT recruited the patients and administered the experimental treatment. AET set the methods for the clinical trial and the analysis of data. All authors contributed to prepare the manuscript.</offsets></p></sec><sec><title><offsets xml_i="26910" xml_f="26933" txt_i="19806" txt_f="19829">Pre-publication history</offsets></title><p><offsets xml_i="26944" xml_f="27008" txt_i="19830" txt_f="19894">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2431/6/17/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We would like to aknowledge Francesco D'Orio for his work in preparing the experimental treatment through loading erythrocytes with dexamethasone.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Konstan</surname><given-names>MW</given-names></name></person-group><article-title>Current understanding of the inflammatory process in Cystic Fibrosis. Onset and etiology</article-title><source>Pediatr Pulmonol</source><year>1997</year><volume>24</volume><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">9292910</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1099-0496(199708)24:2&lt;137::AID-PPUL13&gt;3.0.CO;2-3</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>TZ</given-names></name></person-group><article-title>Early Pulmonary inflammation in infants with cystic fibrosis</article-title><source>Am J Resp Crit Care Med</source><year>1995</year><volume>151</volume><fpage>1075</fpage><lpage>1082</lpage><pub-id pub-id-type="pmid">7697234</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dakin</surname><given-names>CJ</given-names></name><name><surname>Numa</surname><given-names>AH</given-names></name><name><surname>He</surname><given-names>Wang</given-names></name><name><surname>Morton</surname><given-names>JR</given-names></name><name><surname>Vertzyas</surname><given-names>CC</given-names></name></person-group><article-title>Inflammation, Infection and pulmonary function in infants and Young children with cystic fibrosis</article-title><source>Am J Resp Crit Care Med</source><year>2002</year><volume>165</volume><fpage>904</fpage><lpage>010</lpage><pub-id pub-id-type="pmid">11934712</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oermann</surname><given-names>CM</given-names></name></person-group><article-title>Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future</article-title><source>Curr Opin Investig Drugs </source><year>2001</year><volume>2</volume><fpage>900</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11757788</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balfour-Lynn</surname><given-names>IM</given-names></name></person-group><article-title>Corticosteroids and ibuprofen in Cystic Fibrosis</article-title><source>Thorax</source><year>1999</year><volume>54</volume><fpage>657</fpage><pub-id pub-id-type="pmid">10438308</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dakin</surname><given-names>CJ</given-names></name><name><surname>Numa</surname><given-names>ALL</given-names></name><name><surname>Wang</surname><given-names>IJ</given-names></name><name><surname>Horton</surname><given-names>JR</given-names></name><name><surname>Vertzyas</surname><given-names>CC</given-names></name><name><surname>Ilenry</surname><given-names>RL</given-names></name></person-group><article-title>Inflammation, Infection and Pulmonary function in infants and young children with cystic fibrosis</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>165</volume><fpage>904</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">11934712</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carpagnano</surname><given-names>GE</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname></surname><given-names>DM</given-names></name><name><surname>Hodson</surname><given-names>ME</given-names></name><name><surname>Kharitonov</surname><given-names>SA</given-names></name></person-group><article-title>Increased leukotriene B4 and Interleukin-6 in exhaled breath condensate in cystic fibrosis</article-title><source>Am J Resp Crit Care Med</source><year>2003</year><volume>167</volume><fpage>1109</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">12684249</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200203-179OC</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saiman</surname><given-names>L</given-names></name><name><surname>Marshall</surname><given-names>BC</given-names></name><name><surname>Mayer-Hamblett</surname><given-names>N</given-names></name><name><surname>Burns</surname><given-names>JL</given-names></name><name><surname>Quittner</surname><given-names>A</given-names></name><name><surname>Cibene</surname><given-names>DA</given-names></name><name><surname>Coquillette</surname><given-names>S</given-names></name><name><surname>Fieberg</surname><given-names>AY</given-names></name><name><surname>Accurso</surname><given-names>FJ</given-names></name><name><surname>Campbell</surname><given-names>PW</given-names></name></person-group><article-title>Azithromycin in patients with cystic fibrosis chronically infected woth Pseudomonas aeruginosa: a randomized controlled trial</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>1749</fpage><lpage>1756</lpage><pub-id pub-id-type="pmid">14519709</pub-id><pub-id pub-id-type="doi">10.1001/jama.290.13.1749</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auerbach</surname><given-names>AS</given-names></name></person-group><article-title>Alternative-Day prednisolone reduces morbidity and improves pulmonary function in Cystic Fibrosis</article-title><source>Lancet</source><year>1985</year><volume>2</volume><fpage>686</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">2863676</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(85)92929-0</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eigen</surname><given-names>H</given-names></name></person-group><article-title>A multicenter study of alternative -day prednisone therapy in patients with Cystic Fibrosis</article-title><source>J Pediatrics</source><year>1995</year><volume>126</volume><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(95)70343-8</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hui-Chuan</surname><given-names>L</given-names></name></person-group><article-title>Risk of persistent growth impairment after alternative-day predisone treatment in children with cystic fibrosis</article-title><source>N Engl J Med</source><year>2004</year><volume>342</volume><fpage>851</fpage><lpage>9</lpage></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Konstan</surname><given-names>NW</given-names></name></person-group><article-title>Effect of High-dose Ibuprofen in patients with Cystic Fibrosis</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><fpage>848</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">7503838</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199503303321303</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oermann</surname><given-names>CM</given-names></name></person-group><article-title>The use of anti-inflammatory medications in cystic fibrosis. Trend and physician attitudes</article-title><source>Chest</source><year>1999</year><volume>115</volume><fpage>1051</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1378/chest.115.4.1053</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magnani</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>L</given-names></name><name><surname>D'ascenzo</surname><given-names>M</given-names></name><name><surname>Panzani</surname><given-names>I</given-names></name><name><surname>Bigi</surname><given-names>L</given-names></name><name><surname>Zanella</surname><given-names>A</given-names></name></person-group><article-title>Erythrocyte engineering for drug delivery and targeting</article-title><source>Biotechnol Appl Biochem</source><year>1998</year><volume>28</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9693082</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>L</given-names></name><name><surname>Serafini</surname><given-names>S</given-names></name><name><surname>Cenerini</surname><given-names>L</given-names></name><name><surname>Picardi</surname><given-names>F</given-names></name><name><surname>Bigi</surname><given-names>L</given-names></name><name><surname>Panzani</surname><given-names>I</given-names></name><name><surname>Magnani</surname><given-names>M</given-names></name></person-group><article-title>Erytrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease</article-title><source>Biotechnol Appl Biochem</source><year>2001</year><volume>33</volume><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">11277860</pub-id><pub-id pub-id-type="doi">10.1042/BA20000087</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ropars</surname><given-names>C</given-names></name><name><surname>Chassaigne</surname><given-names>M</given-names></name><name><surname>Villereal</surname><given-names>MC</given-names></name><name><surname>Avenard</surname><given-names>G</given-names></name><name><surname>Hurel</surname><given-names>C</given-names></name><name><surname>Nicolai</surname><given-names>C</given-names></name></person-group><article-title>Resealed red blood cells as a new blood transfusion product</article-title><source>Bibl Haematol</source><year>1985</year><volume>51</volume><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">4004766</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>L</given-names></name><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>D'Orio</surname><given-names>F</given-names></name><name><surname>Damonte</surname><given-names>G</given-names></name><name><surname>Serafini</surname><given-names>S</given-names></name><name><surname>Bigi</surname><given-names>L</given-names></name><name><surname>Panzani</surname><given-names>I</given-names></name><name><surname>Nerolli</surname><given-names>G</given-names></name><name><surname>Dallapiccola</surname><given-names>B</given-names></name><name><surname>Panunzi</surname><given-names>S</given-names></name><name><surname>Di Carlo</surname><given-names>P</given-names></name><name><surname>Bella</surname><given-names>S</given-names></name><name><surname>Magnani</surname><given-names>M</given-names></name></person-group><article-title>Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients</article-title><source>Blood Cells Mol Dis</source><year>2004</year><volume>33</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15223012</pub-id><pub-id pub-id-type="doi">10.1016/j.bcmd.2004.04.004</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>LE</given-names></name><name><surname>Cooke</surname><given-names>RE</given-names></name></person-group><article-title>A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis</article-title><source>Pediatrics</source><year>1959</year><volume>23</volume><fpage>545</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">13633369</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shwachman</surname><given-names>H</given-names></name><name><surname>Kulczycki</surname><given-names>LL</given-names></name></person-group><article-title>Long-term study of 105 patients with cystic fibrosis: Studies made over a 5 to 14 year period</article-title><source>Am J Dis Child</source><year>1958</year><volume>96</volume><fpage>6</fpage></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chrispin</surname><given-names>AR</given-names></name><name><surname>Norman</surname><given-names>AP</given-names></name></person-group><article-title>The systematic evaluation of the chest radiograph in cystic fibrosis</article-title><source>Pediatr Radiol</source><year>1974</year><volume>2</volume><fpage>101</fpage><pub-id pub-id-type="pmid">15822331</pub-id><pub-id pub-id-type="doi">10.1007/BF01314939</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname><given-names>M</given-names></name><name><surname>Emerson</surname><given-names>J</given-names></name><name><surname>Williams-Warren</surname><given-names>J</given-names></name><name><surname>Pepe</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Montgomery</surname><given-names>A</given-names></name><name><surname>Ramsey</surname><given-names>B</given-names></name></person-group><article-title>Defining a pulmonary exacerbation in Cystic Fibrosis</article-title><source>J Pediatr</source><year>2001</year><volume>139</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">11562614</pub-id><pub-id pub-id-type="doi">10.1067/mpd.2001.117288</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hubeau</surname><given-names>C</given-names></name><name><surname>Le Naour</surname><given-names>R</given-names></name><name><surname>Abely</surname><given-names>M</given-names></name><name><surname>Hinnrasky</surname><given-names>J</given-names></name><name><surname>Guenounou</surname><given-names>M</given-names></name><name><surname>Gaillard</surname><given-names>D</given-names></name><name><surname>Puchelle</surname><given-names>E</given-names></name></person-group><article-title>Dysregulation of IL-" and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients</article-title><source>Clin Exp Immunol</source><year>2004</year><volume>135</volume><fpage>528</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">15008989</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2249.2003.02385.x</pub-id></citation></ref></ref-list></back></article>